XXII

22nd Century Group Inc XXII

Market Open
9 May, 14:30
NASDAQ (CM) NASDAQ (CM)
$
1. 57
-0.08
-5.14%
$
9.58M Market Cap
- P/E Ratio
0% Div Yield
88,272 Volume
-6.88 Eps
$ 1.66
Previous Close
Day Range
1.57 1.68
Year Range
1.45 175.2

XXII Chart

22nd Century Group Inc Profile

Tobacco Industry
Consumer Defensive Sector
Mr. James A. Mish CEO
NASDAQ (CM) Exchange
US90137F1030 ISIN
US Country
64 Employees
- Last Dividend
2 Apr 2024 Last Split
26 Jan 2011 IPO Date

Overview

22nd Century Group, Inc. is a pioneering company in the field of agricultural biotechnology, concentrating its efforts on tobacco harm reduction and the advancement of health and wellness through innovative plant science. This involves the development of reduced nicotine tobacco products and leveraging plant biotechnology for life science and consumer product advancements. Founded in 1998 and based in Buffalo, New York, the company engages in scientific research to achieve its objectives, including collaborations aimed at enhancing the properties of hemp and cannabis for both medical and agricultural applications.

Products and Services

  • VLN King & VLN Menthol King Cigarettes: These products represent the company’s forefront innovation, characterized by their very low nicotine content. Tailored to address the public health concern regarding nicotine addiction, these cigarettes aim at providing a safer alternative for smokers. The VLN King and VLN Menthol King are designed not only to reduce smokers' nicotine consumption but also to potentially aid in smoking cessation efforts.
  • SPECTRUM Research Cigarettes: Specially developed for use in independent clinical studies, SPECTRUM research cigarettes serve an important role in tobacco research. They are utilized by scientists and health professionals to investigate the impact of nicotine and other tobacco product constituents on health, behavior, and genetics. By providing a controlled product for clinical research, 22nd Century Group, Inc. significantly contributes to advances in public health knowledge regarding tobacco use.
  • Hemp/Cannabis Plant Development: In collaboration with Keygene N.V., 22nd Century Group, Inc. is also making strides in the development of hemp and cannabis plants with enhanced cannabinoid profiles and agronomic traits. This initiative aims to leverage plant biotechnology for medical, therapeutic, and agricultural purposes, offering potentially revolutionary applications in these fields. The effort underscores the company’s commitment to utilizing advanced biotechnologies to improve the quality and functionality of plant-derived products.

Contact Information

Address: 321 Farmington Road, Mocksville, NC, United States, 27028
Phone: (716) 270-1523